Replies to post #377621 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

"Could ipix have one partner for vital, one for bacterial, one for fungal, so on and do on?"


In a nutshell, yes.

It's not uncommon for the same compound to be licensed to different partners for different indications, but it's much simpler if each indication has one or more unique dosage forms so that it's clear who has sold what.

Usually the first partner will have right of first refusal for additional indications and dosage forms.

[BonelessCat]

Wish I could answer that. However, I think the most likely outcome isn’t a partnership, but a buyout. The decision then would be the new owner. If the trial results show high safety and very mild adverse events, a billion is likely. Otherwise all bets are as good as mine.